Concepts (161)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 13 | 2023 | 371 | 1.740 |
Why?
|
| Glioblastoma | 11 | 2023 | 219 | 1.470 |
Why?
|
| Meningioma | 4 | 2023 | 54 | 0.710 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2019 | 29 | 0.620 |
Why?
|
| DNA Mismatch Repair | 3 | 2021 | 42 | 0.560 |
Why?
|
| Neoplastic Syndromes, Hereditary | 3 | 2021 | 14 | 0.510 |
Why?
|
| Seizures | 3 | 2021 | 279 | 0.460 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2013 | 63 | 0.450 |
Why?
|
| Meningeal Neoplasms | 2 | 2023 | 42 | 0.410 |
Why?
|
| DNA Repair Enzymes | 3 | 2021 | 53 | 0.410 |
Why?
|
| DNA Repair | 2 | 2022 | 127 | 0.380 |
Why?
|
| Colorectal Neoplasms | 3 | 2021 | 560 | 0.350 |
Why?
|
| Pentoxifylline | 1 | 2006 | 12 | 0.290 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2018 | 116 | 0.270 |
Why?
|
| Mutation | 4 | 2020 | 1213 | 0.270 |
Why?
|
| Vasodilator Agents | 1 | 2006 | 138 | 0.270 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2006 | 98 | 0.260 |
Why?
|
| Germ-Line Mutation | 2 | 2022 | 43 | 0.260 |
Why?
|
| Electroencephalography | 3 | 2021 | 418 | 0.240 |
Why?
|
| DNA Replication | 2 | 2022 | 167 | 0.230 |
Why?
|
| Re-Irradiation | 1 | 2022 | 1 | 0.220 |
Why?
|
| B7-H1 Antigen | 1 | 2022 | 30 | 0.210 |
Why?
|
| Microsatellite Instability | 1 | 2020 | 39 | 0.190 |
Why?
|
| DNA Repair-Deficiency Disorders | 1 | 2020 | 1 | 0.190 |
Why?
|
| Biomarkers, Tumor | 3 | 2022 | 508 | 0.190 |
Why?
|
| Dendritic Cells | 2 | 2023 | 201 | 0.190 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 2020 | 35 | 0.190 |
Why?
|
| Oncolytic Viruses | 1 | 2020 | 17 | 0.190 |
Why?
|
| Neurofibromin 2 | 1 | 2020 | 10 | 0.190 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2020 | 14 | 0.190 |
Why?
|
| Humans | 25 | 2023 | 68525 | 0.190 |
Why?
|
| Neoplasms | 3 | 2022 | 1660 | 0.180 |
Why?
|
| Quinolones | 1 | 2020 | 60 | 0.180 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2020 | 756 | 0.180 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 100 | 0.180 |
Why?
|
| Glioma | 1 | 2020 | 140 | 0.170 |
Why?
|
| Benzimidazoles | 1 | 2020 | 128 | 0.170 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2020 | 235 | 0.170 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2019 | 36 | 0.170 |
Why?
|
| DNA Methylation | 1 | 2020 | 192 | 0.170 |
Why?
|
| Status Epilepticus | 1 | 2019 | 74 | 0.170 |
Why?
|
| Allyl Compounds | 1 | 2018 | 29 | 0.160 |
Why?
|
| Sulfides | 1 | 2018 | 43 | 0.160 |
Why?
|
| Cancer Vaccines | 1 | 2018 | 61 | 0.160 |
Why?
|
| Genetic Testing | 1 | 2019 | 159 | 0.150 |
Why?
|
| Histone Deacetylases | 1 | 2018 | 99 | 0.150 |
Why?
|
| Young Adult | 6 | 2022 | 5708 | 0.150 |
Why?
|
| Cell Line, Tumor | 5 | 2020 | 1849 | 0.150 |
Why?
|
| Adult | 11 | 2022 | 21375 | 0.140 |
Why?
|
| Recurrence | 2 | 2023 | 948 | 0.140 |
Why?
|
| Early Detection of Cancer | 1 | 2021 | 439 | 0.140 |
Why?
|
| Gamma Rays | 1 | 2015 | 64 | 0.140 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2015 | 30 | 0.140 |
Why?
|
| Gadolinium | 1 | 2016 | 88 | 0.130 |
Why?
|
| Limonins | 1 | 2015 | 10 | 0.130 |
Why?
|
| Catechols | 1 | 2015 | 14 | 0.130 |
Why?
|
| Flavones | 1 | 2015 | 11 | 0.130 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2016 | 86 | 0.130 |
Why?
|
| Lanosterol | 1 | 2015 | 11 | 0.130 |
Why?
|
| Fatty Alcohols | 1 | 2015 | 14 | 0.130 |
Why?
|
| Heptanoic Acids | 1 | 2015 | 28 | 0.130 |
Why?
|
| Sesquiterpenes | 1 | 2015 | 41 | 0.130 |
Why?
|
| Necrosis | 1 | 2015 | 239 | 0.130 |
Why?
|
| Radiation Injuries | 1 | 2015 | 97 | 0.130 |
Why?
|
| Triterpenes | 1 | 2015 | 40 | 0.130 |
Why?
|
| Prospective Studies | 4 | 2023 | 3702 | 0.120 |
Why?
|
| Injections, Spinal | 1 | 2013 | 18 | 0.120 |
Why?
|
| Cerebrospinal Fluid | 1 | 2013 | 23 | 0.120 |
Why?
|
| Female | 10 | 2022 | 38015 | 0.120 |
Why?
|
| Epigenesis, Genetic | 1 | 2015 | 163 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 1 | 2016 | 510 | 0.110 |
Why?
|
| Skin | 1 | 2016 | 451 | 0.110 |
Why?
|
| Contrast Media | 1 | 2016 | 594 | 0.110 |
Why?
|
| Male | 11 | 2022 | 37281 | 0.110 |
Why?
|
| Child | 5 | 2022 | 6400 | 0.100 |
Why?
|
| Retrospective Studies | 5 | 2023 | 7264 | 0.100 |
Why?
|
| Treatment Outcome | 3 | 2018 | 7028 | 0.100 |
Why?
|
| Apoptosis | 4 | 2020 | 1640 | 0.090 |
Why?
|
| Tumor Microenvironment | 2 | 2022 | 211 | 0.090 |
Why?
|
| Adolescent | 4 | 2022 | 8903 | 0.090 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2020 | 222 | 0.090 |
Why?
|
| Survival Analysis | 2 | 2022 | 714 | 0.080 |
Why?
|
| Child, Preschool | 3 | 2021 | 3185 | 0.080 |
Why?
|
| Benzamides | 2 | 2020 | 156 | 0.070 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2018 | 304 | 0.070 |
Why?
|
| Middle Aged | 5 | 2021 | 21119 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 1 | 2006 | 186 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 1070 | 0.070 |
Why?
|
| Aged | 4 | 2021 | 14842 | 0.070 |
Why?
|
| Prevalence | 2 | 2021 | 1609 | 0.070 |
Why?
|
| Prognosis | 2 | 2021 | 2093 | 0.060 |
Why?
|
| Cell Proliferation | 2 | 2020 | 1173 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 3256 | 0.060 |
Why?
|
| Bevacizumab | 1 | 2022 | 34 | 0.050 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2023 | 125 | 0.050 |
Why?
|
| Preservation, Biological | 1 | 2022 | 11 | 0.050 |
Why?
|
| Double-Blind Method | 1 | 2006 | 1737 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2006 | 929 | 0.050 |
Why?
|
| Tissue Preservation | 1 | 2022 | 44 | 0.050 |
Why?
|
| Risk | 1 | 2023 | 563 | 0.050 |
Why?
|
| Vaccination | 1 | 2023 | 182 | 0.050 |
Why?
|
| RNA | 1 | 2022 | 171 | 0.050 |
Why?
|
| DNA Modification Methylases | 1 | 2020 | 24 | 0.050 |
Why?
|
| Sulfones | 1 | 2020 | 45 | 0.050 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2020 | 22 | 0.050 |
Why?
|
| bcl-X Protein | 1 | 2020 | 36 | 0.050 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2020 | 57 | 0.050 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2020 | 111 | 0.050 |
Why?
|
| Triazines | 1 | 2020 | 48 | 0.050 |
Why?
|
| Imidazoles | 1 | 2020 | 175 | 0.040 |
Why?
|
| Caspase 3 | 1 | 2020 | 233 | 0.040 |
Why?
|
| Population Surveillance | 1 | 2021 | 285 | 0.040 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2020 | 194 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 467 | 0.040 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 1 | 2019 | 20 | 0.040 |
Why?
|
| Pyrimidines | 1 | 2020 | 178 | 0.040 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2019 | 26 | 0.040 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2019 | 32 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2020 | 212 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2020 | 2688 | 0.040 |
Why?
|
| Survival Rate | 1 | 2021 | 1055 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2020 | 331 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2020 | 332 | 0.040 |
Why?
|
| DNA Polymerase III | 1 | 2017 | 3 | 0.040 |
Why?
|
| DNA Polymerase II | 1 | 2017 | 5 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2018 | 238 | 0.040 |
Why?
|
| Endpoint Determination | 1 | 2018 | 82 | 0.040 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2017 | 7 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2020 | 799 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2022 | 1341 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2020 | 331 | 0.040 |
Why?
|
| Cell Line | 1 | 2021 | 1752 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2017 | 218 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2016 | 2222 | 0.040 |
Why?
|
| Aged, 80 and over | 1 | 2006 | 4843 | 0.040 |
Why?
|
| Astrocytes | 1 | 2018 | 270 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2015 | 196 | 0.030 |
Why?
|
| Phenotype | 1 | 2019 | 946 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 1054 | 0.030 |
Why?
|
| Caspases | 1 | 2015 | 194 | 0.030 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2015 | 57 | 0.030 |
Why?
|
| DNA Fragmentation | 1 | 2015 | 85 | 0.030 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2015 | 64 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 785 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 1465 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2019 | 1548 | 0.030 |
Why?
|
| Wnt Signaling Pathway | 1 | 2015 | 57 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2019 | 700 | 0.030 |
Why?
|
| Hydroxamic Acids | 1 | 2015 | 84 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 1745 | 0.030 |
Why?
|
| Oligopeptides | 1 | 2015 | 152 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2015 | 852 | 0.030 |
Why?
|
| Fatty Acids | 1 | 2015 | 222 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2015 | 954 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2019 | 2356 | 0.030 |
Why?
|
| Neurons | 1 | 2018 | 881 | 0.030 |
Why?
|
| Kidney | 1 | 2016 | 945 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2015 | 2083 | 0.020 |
Why?
|
| Animals | 2 | 2018 | 20877 | 0.020 |
Why?
|
| United States | 1 | 2021 | 7335 | 0.020 |
Why?
|
| Rats | 1 | 2015 | 5300 | 0.020 |
Why?
|